Effect of Tranilast on restenosis of Arteriovenous Fistulas for Hemodialysis.

Effect of Tranilast on restenosis of Arteriovenous Fistulas for Hemodialysis. - Effect of Tranilast on restenosis of Arteriovenous Fistulas for Hemodialysis.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004251

Enrollment

Registered

2010-12-01

Start date

2010-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemodialysis patients

Interventions

It is the crossover trials which is receving tranilast for one year and non-medication for one year. It is the crossover trials which is receving tranilast for one year and non-medication for one year

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who visit our hospital at regular intervals and undergo PTA are recruited.

Exclusion criteria

Exclusion criteria: The exclusion criteria are follows; 1) newly receiving the antiplatelet agent or antithrombocytic agent or anticoagulant agent or anticoagulant agent or vasodilating age within three monthes 2) drug allergy to tranilast

Design outcomes

Primary

Measure	Time frame
The primary outcome is number of PTA times for one year after patients receive tranilast.	—

Secondary

Measure	Time frame
The secondary outcome is failure of the fistula or graft determined by ultrasound.	—

Countries

Japan

Contacts

Public ContactKatsuomi Matsui

St. Marianna University School of Medicine Department of Nephrology and Hypertension, Internal Medicine

fybnt014@yahoo.co.jp044-977-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026